Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,108
archived clinical trials in
Lupus

An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate Efficacy and Safety of Treatment With CNTO 136 Administered Intravenously in Subjects With Active Lupus Nephritis
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Chattanooga, TN
An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate Efficacy and Safety of Treatment With CNTO 136 Administered Intravenously in Subjects With Active Lupus Nephritis
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate Efficacy and Safety of Treatment With CNTO 136 Administered Intravenously in Subjects With Active Lupus Nephritis
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Los Angeles, CA
An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate Efficacy and Safety of Treatment With CNTO 136 Administered Intravenously in Subjects With Active Lupus Nephritis
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate Efficacy and Safety of Treatment With CNTO 136 Administered Intravenously in Subjects With Active Lupus Nephritis
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Chicago, IL
An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate Efficacy and Safety of Treatment With CNTO 136 Administered Intravenously in Subjects With Active Lupus Nephritis
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate Efficacy and Safety of Treatment With CNTO 136 Administered Intravenously in Subjects With Active Lupus Nephritis
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Lake Success, NY
An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate Efficacy and Safety of Treatment With CNTO 136 Administered Intravenously in Subjects With Active Lupus Nephritis
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Lake Success, NY
Click here to add this to my saved trials
An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate Efficacy and Safety of Treatment With CNTO 136 Administered Intravenously in Subjects With Active Lupus Nephritis
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Columbus, OH
An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate Efficacy and Safety of Treatment With CNTO 136 Administered Intravenously in Subjects With Active Lupus Nephritis
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate Efficacy and Safety of Treatment With CNTO 136 Administered Intravenously in Subjects With Active Lupus Nephritis
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Duncansville, PA
An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate Efficacy and Safety of Treatment With CNTO 136 Administered Intravenously in Subjects With Active Lupus Nephritis
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Duncansville, PA
Click here to add this to my saved trials
An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate Efficacy and Safety of Treatment With CNTO 136 Administered Intravenously in Subjects With Active Lupus Nephritis
Status: Enrolling
Updated:  2/25/2016
Clinical Research Facility
mi
from
Carrollton, TX
An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate Efficacy and Safety of Treatment With CNTO 136 Administered Intravenously in Subjects With Active Lupus Nephritis
Status: Enrolling
Updated: 2/25/2016
Clinical Research Facility
mi
from
Carrollton, TX
Click here to add this to my saved trials
An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate Efficacy and Safety of Treatment With CNTO 136 Administered Intravenously in Subjects With Active Lupus Nephritis
Status: Enrolling
Updated:  2/25/2016
Investigational Site
mi
from
Brussels,
An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate Efficacy and Safety of Treatment With CNTO 136 Administered Intravenously in Subjects With Active Lupus Nephritis
Status: Enrolling
Updated: 2/25/2016
Investigational Site
mi
from
Brussels,
Click here to add this to my saved trials
Serologically Active, Clinically Stable Systemic Lupus Erythematosus
Serologically Active, Clinically Stable Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  3/2/2016
Office of Betty Diamond, M.D.
mi
from
Bronx, NY
Serologically Active, Clinically Stable Systemic Lupus Erythematosus
Serologically Active, Clinically Stable Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 3/2/2016
Office of Betty Diamond, M.D.
mi
from
Bronx, NY
Click here to add this to my saved trials
Serologically Active, Clinically Stable Systemic Lupus Erythematosus
Serologically Active, Clinically Stable Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  3/2/2016
North Shore-Long Island Jewish Health System
mi
from
New Hyde Park, NY
Serologically Active, Clinically Stable Systemic Lupus Erythematosus
Serologically Active, Clinically Stable Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 3/2/2016
North Shore-Long Island Jewish Health System
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Serologically Active, Clinically Stable Systemic Lupus Erythematosus
Serologically Active, Clinically Stable Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  3/2/2016
Lenox Hill Hospital
mi
from
New York, NY
Serologically Active, Clinically Stable Systemic Lupus Erythematosus
Serologically Active, Clinically Stable Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 3/2/2016
Lenox Hill Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Dexamethasone Treatment for Congenital Heart Block (CHB) in Newborns With Lupus
Study of Dexamethasone in Neonatal Lupus Congenital Heart Block; PRIDE (PR Interval and Dexamethasone Evaluation) in Congenital Heart Block
Status: Enrolling
Updated:  3/10/2016
Yale University Medical Center
mi
from
New Haven, CT
Dexamethasone Treatment for Congenital Heart Block (CHB) in Newborns With Lupus
Study of Dexamethasone in Neonatal Lupus Congenital Heart Block; PRIDE (PR Interval and Dexamethasone Evaluation) in Congenital Heart Block
Status: Enrolling
Updated: 3/10/2016
Yale University Medical Center
mi
from
New Haven, CT
Click here to add this to my saved trials
Dexamethasone Treatment for Congenital Heart Block (CHB) in Newborns With Lupus
Study of Dexamethasone in Neonatal Lupus Congenital Heart Block; PRIDE (PR Interval and Dexamethasone Evaluation) in Congenital Heart Block
Status: Enrolling
Updated:  3/10/2016
St. Barnabas Medical Center
mi
from
Livingston, NJ
Dexamethasone Treatment for Congenital Heart Block (CHB) in Newborns With Lupus
Study of Dexamethasone in Neonatal Lupus Congenital Heart Block; PRIDE (PR Interval and Dexamethasone Evaluation) in Congenital Heart Block
Status: Enrolling
Updated: 3/10/2016
St. Barnabas Medical Center
mi
from
Livingston, NJ
Click here to add this to my saved trials
Dexamethasone Treatment for Congenital Heart Block (CHB) in Newborns With Lupus
Study of Dexamethasone in Neonatal Lupus Congenital Heart Block; PRIDE (PR Interval and Dexamethasone Evaluation) in Congenital Heart Block
Status: Enrolling
Updated:  3/10/2016
Hospital For Joint Diseases
mi
from
New York, NY
Dexamethasone Treatment for Congenital Heart Block (CHB) in Newborns With Lupus
Study of Dexamethasone in Neonatal Lupus Congenital Heart Block; PRIDE (PR Interval and Dexamethasone Evaluation) in Congenital Heart Block
Status: Enrolling
Updated: 3/10/2016
Hospital For Joint Diseases
mi
from
New York, NY
Click here to add this to my saved trials
Dexamethasone Treatment for Congenital Heart Block (CHB) in Newborns With Lupus
Study of Dexamethasone in Neonatal Lupus Congenital Heart Block; PRIDE (PR Interval and Dexamethasone Evaluation) in Congenital Heart Block
Status: Enrolling
Updated:  3/10/2016
New York Univ. Medical Center
mi
from
New York, NY
Dexamethasone Treatment for Congenital Heart Block (CHB) in Newborns With Lupus
Study of Dexamethasone in Neonatal Lupus Congenital Heart Block; PRIDE (PR Interval and Dexamethasone Evaluation) in Congenital Heart Block
Status: Enrolling
Updated: 3/10/2016
New York Univ. Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Birmingham, AL
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Phoenix, AZ
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Tucson, AZ
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Long Beach, CA
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Los Angeles, CA
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Upland, CA
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Upland, CA
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Washington,
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Washington,
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Aventura, FL
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Aventura, FL
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Orlando, FL
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Tampa, FL
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Tampa, FL
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Atlanta, GA
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Chicago, IL
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Munster, IN
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Munster, IN
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Kansas City, KA
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Kansas City, KA
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Louisville, KY
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Louisville, KY
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Baton Rouge, LA
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Baltimore, MD
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Cumberland, MD
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Cumberland, MD
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Hagerstown, MD
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Hagerstown, MD
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Ann Arbor, MI
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Lansing, MI
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Lansing, MI
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Bronx, NY
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Bronx, NY
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Brooklyn, NY
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Brooklyn, NY
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Great Neck, NY
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Great Neck, NY
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Manhasset, NY
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Manhasset, NY
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
New York, NY
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Rochester, NY
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Rochester, NY
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Smithtown, NY
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Smithtown, NY
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Chapel Hill, NC
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Greenville, NC
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Greenville, NC
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Winston-Salem, NC
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Columbus, OH
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Columbus, OH
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Dayton, OH
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Dayton, OH
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Oklahoma City, OK
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Tulsa, OK
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Tulsa, OK
Click here to add this to my saved trials